Andrew Lo at BIO22 (J.T. MacMillan Photography for Endpoints News)
March 1, 2024 08:00 AM EST
Financing
Cell/Gene Tx

Ex­clu­sive: Backed by MIT’s An­drew Lo, Quan­tile Health rais­es $6M to bol­ster gene ther­a­py ac­cess

Jared Whitlock

Features Editor

In a bid to over­come some of the com­mer­cial chal­lenges faced by ex­pen­sive new gene ther­a­pies, Quan­tile Health has raised $6 mil­lion for a fi­nan­cial …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times